Article Details

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B | BioPharma Dive

Retrieved on: 2025-06-30 16:06:14

Tags for this article:

Click the tags to see associated articles and topics

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B | BioPharma Dive. View article details on hiswai:

Excerpt

In vivo CAR-T could offer a more convenient alternative in oncology, where AbbVie is already working with partner Umoja Biopharma. But it also could ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo